54 records – page 1 of 3.

Select Title Policy Type Year
EspAddText
EspRemoveText
Authorizing Cannabis for Medical Purposes Policy document 2020
EspAddText
EspRemoveText
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act) Parliamentary submission 2014
EspAddText
EspRemoveText
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act) Parliamentary submission 2015
EspAddText
EspRemoveText
Bill C-17 An Act to amend the Food and Drugs Act Parliamentary submission 2014
EspAddText
EspRemoveText
Bill C-45: The Cannabis Act Parliamentary submission 2017
EspAddText
EspRemoveText
Bill C-45: The Cannabis Act Parliamentary submission 2018
EspAddText
EspRemoveText
Canada’s lower-risk cannabis use guidelines (LRCUG) Policy endorsement 2017
EspAddText
EspRemoveText
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase Parliamentary submission 2014
EspAddText
EspRemoveText
Cannabis for Medical Purposes Policy document 2019
EspAddText
EspRemoveText
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology - Prescription Drugs: Clinical Trials and Approval Parliamentary submission 2012
EspAddText
EspRemoveText
CMA Recommendations on Vaccine Equity and Intellectual Property Parliamentary submission 2022
EspAddText
EspRemoveText
CMA Response: Health Canada's Medical Marijuana Regulatory Proposal Parliamentary submission 2013
EspAddText
EspRemoveText
CMA response to patented medicines regulations consultations Response to consultation 2017
EspAddText
EspRemoveText
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts Parliamentary submission 2017
EspAddText
EspRemoveText
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts Parliamentary submission 2018
EspAddText
EspRemoveText
CMA's Response to Health Canada's Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) Response to consultation 2015
EspAddText
EspRemoveText
CMA's Submission to the House of Commons Standing Committee on Health: Drug Shortages Parliamentary submission 2012
EspAddText
EspRemoveText
CMA's Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety Parliamentary submission 2014
EspAddText
EspRemoveText
CMA's Submission to the Senate Committee on Social Affairs, Science and Technology - Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals Parliamentary submission 2012
EspAddText
EspRemoveText
CMA submission to the study of Bill C-37 Parliamentary submission 2017

54 records – page 1 of 3.